LungLife AI, Inc. Share Price Deutsche Boerse AG

Equities

9H4

USU5500L1045

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 14:29:01 14/06/2024 BST 5-day change 1st Jan Change
0.184 EUR 0.00% Intraday chart for LungLife AI, Inc. -5.15% -74.79%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 100K 93.44K 7.89M Sales 2025 * 500K 467K 39.43M Capitalization 6.61M 6.18M 521M
Net income 2024 * -3M -2.8M -237M Net income 2025 * - 0 0 EV / Sales 2024 * 60.1 x
Net cash position 2024 * 600K 561K 47.31M Net cash position 2025 * 500K 467K 39.43M EV / Sales 2025 * 12.2 x
P/E ratio 2024 *
-1.6 x
P/E ratio 2025 *
53.6 x
Employees 15
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.29%
More Fundamentals * Assessed data
Dynamic Chart
1 week-5.15%
Current month-9.80%
1 month-34.75%
3 months-42.14%
6 months-76.71%
Current year-74.79%
More quotes
1 week
0.17
Extreme 0.171
0.20
1 month
0.17
Extreme 0.171
0.28
Current year
0.17
Extreme 0.171
0.75
1 year
0.17
Extreme 0.171
1.56
3 years
0.17
Extreme 0.171
2.28
5 years
0.17
Extreme 0.171
2.28
10 years
0.17
Extreme 0.171
2.28
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 -
Director of Finance/CFO 61 -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 67 07/07/21
Director/Board Member 58 07/07/21
Director of Finance/CFO 61 -
More insiders
Date Price Change
14/06/24 0.184 0.00%
13/06/24 0.184 0.00%
12/06/24 0.184 -6.12%
11/06/24 0.196 +0.51%
10/06/24 0.195 +0.52%

Delayed Quote Deutsche Boerse AG, June 14, 2024 at 02:29 pm

More quotes
LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.17 GBP
Average target price
2.2 GBP
Spread / Average Target
+1,194.12%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW